Postepy dermatologii i alergologii · 2024
Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jun-Ting Tang, Ying Tu, Dong-Jie Sun, Xiang Nong, Can Cao, Si-Cheng Du, Yue-Ting Cun, Li He
Аннотация
INTRODUCTION: Rituximab, a CD20 inhibitor, has swiftly become the primary treatment for pemphigus patients.
AIM: We present 3 cases of pemphigus patients who had undergone rituximab treatment.
MATERIAL AND METHODS: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions. Peripheral blood was collected from the aforementioned 3 patients for the detection of susceptibility genes by using second-generation sequencing.
RESULTS: Notably, a significant resemblance was observed in the HLA profiles of these 3 patients, particularly regarding high-risk alleles associated with rituximab-induced severe cutaneous drug reactions (CDRs). This rare occurrence of severe CDRs post-rituximab administration may be HLA-dependent and linked to HLA-B*15:02:01, HLA-B*15:12 and HLA-B*15:27:01. This pioneering laboratory trial shows the pathological background of rituximab-induced severe cutaneous drug reactions.
CONCLUSIONS: Our findings contribute to the expanding catalogue of potential HLA-B*15 linked to severe CDRs and underscore the importance of vigilance regarding such reactions in pemphigus patients undergoing rituximab therapy.
AIM: We present 3 cases of pemphigus patients who had undergone rituximab treatment.
MATERIAL AND METHODS: After the second intravenous administration of rituximab, the primary rash developed into severe cutaneous drug reactions. Peripheral blood was collected from the aforementioned 3 patients for the detection of susceptibility genes by using second-generation sequencing.
RESULTS: Notably, a significant resemblance was observed in the HLA profiles of these 3 patients, particularly regarding high-risk alleles associated with rituximab-induced severe cutaneous drug reactions (CDRs). This rare occurrence of severe CDRs post-rituximab administration may be HLA-dependent and linked to HLA-B*15:02:01, HLA-B*15:12 and HLA-B*15:27:01. This pioneering laboratory trial shows the pathological background of rituximab-induced severe cutaneous drug reactions.
CONCLUSIONS: Our findings contribute to the expanding catalogue of potential HLA-B*15 linked to severe CDRs and underscore the importance of vigilance regarding such reactions in pemphigus patients undergoing rituximab therapy.